Published in Women's Health Weekly, November 16th, 1998
This clears the popular breast cancer drug, sold by British pharmaceuticals and chemicals giant Zeneca Group Plc under the name Nolvadex, for use in preventing breast cancer in women considered at high risk.
"Breast cancer is the second leading cause of cancer death in American women and accounts for 31 percent of all cancers among women. [This] action provides an important new option for some women at heightened risk of breast cancer," U.S. Department of Health and Human Services Secretary Donna...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly